OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.

The landscape of oncology is undergoing a transformative shift with the emergence of tumor-agnostic approaches, driven by the understanding that cancer treatment can transcend the traditional paradigm ...

New launch replaces slow, fragmented healthcare marketing infrastructure with fast, platform-agnostic activation and ...

“Data-Driven Thinking” is written by members of the media community and contains fresh ideas on the digital revolution in media. Today’s column is written by Matt Greitzer, co-founder at Actable Data.